Home
BMRN
BMRN News

Latest BioMarin Pharmaceutical Inc. (BMRN) News on October 22, 2025

10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know

StockStory

11 days ago

10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know

Can BioMarin (BMRN) Turn PALYNZIQ Success Into a Stronger Rare Disease Growth Story?

Simply Wall St.

19 days ago

Can BioMarin (BMRN) Turn PALYNZIQ Success Into a Stronger Rare Disease Growth Story?

Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors

Insider Monkey

19 days ago

Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors

BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low

Insider Monkey

20 days ago

BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Zacks

20 days ago

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Zacks

a month ago

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

A Fresh Look at BioMarin Pharmaceutical (BMRN) Valuation Following New VOXZOGO and PALYNZIQ Clinical Data

Simply Wall St.

a month ago

A Fresh Look at BioMarin Pharmaceutical (BMRN) Valuation Following New VOXZOGO and PALYNZIQ Clinical Data

BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory

Insider Monkey

a month ago

BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory

New Study Results Highlight BioMarin’s VOXZOGO Efficacy in Children

Insider Monkey

a month ago

New Study Results Highlight BioMarin’s VOXZOGO Efficacy in Children

Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)

StockStory

a month ago

Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Zacks

a month ago

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86

Insider Monkey

2 months ago

Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86

2 Reasons to Watch BMRN and 1 to Stay Cautious

StockStory

2 months ago

2 Reasons to Watch BMRN and 1 to Stay Cautious

BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A

Insider Monkey

4 months ago

BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Zacks

4 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

The Top 5 Analyst Questions From BioMarin Pharmaceutical’s Q1 Earnings Call

StockStory

4 months ago

The Top 5 Analyst Questions From BioMarin Pharmaceutical’s Q1 Earnings Call

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Zacks

4 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Argus Research

4 months ago

BMRN: What does Argus have to say about BMRN?

MT Newswires

4 months ago

BioMarin Pharmaceutical Reports Sustained Efficacy for Hemophilia A Gene Therapy in Five-Year Data

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

PR Newswire

4 months ago

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating

Insider Monkey

4 months ago

Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating

2 Reasons to Watch BMRN and 1 to Stay Cautious

StockStory

4 months ago

2 Reasons to Watch BMRN and 1 to Stay Cautious

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

GlobeNewswire

4 months ago

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

Does The Market Have A Low Tolerance For BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Fundamentals?

Simply Wall St.

4 months ago

Does The Market Have A Low Tolerance For BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Fundamentals?

1 of Wall Street’s Favorite Stock to Target This Week and 2 to Think Twice About

StockStory

4 months ago

1 of Wall Street’s Favorite Stock to Target This Week and 2 to Think Twice About

Jim Cramer on BioMarin: “I Don’t Think It Works Now”

Insider Monkey

4 months ago

Jim Cramer on BioMarin: “I Don’t Think It Works Now”

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

4 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Argus Research

4 months ago

BMRN: Raising target price to $63.00

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks

4 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Here Are All 6 Stocks I've Bought Through 5 Months of 2025

Motley Fool

5 months ago

Here Are All 6 Stocks I've Bought Through 5 Months of 2025

1 Mid-Cap Stock with Exciting Potential and 2 to Avoid

StockStory

5 months ago

1 Mid-Cap Stock with Exciting Potential and 2 to Avoid

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?

Zacks

5 months ago

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?

2 Value Stocks with Exciting Potential and 1 to Steer Clear Of

StockStory

5 months ago

2 Value Stocks with Exciting Potential and 1 to Steer Clear Of

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

StockStory

5 months ago

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Zacks

5 months ago

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Zacks

5 months ago

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks

5 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Argus Research

5 months ago

BMRN: What does Argus have to say about BMRN?

Biotech Alert: Searches spiking for these stocks today

TipRanks

5 months ago

Biotech Alert: Searches spiking for these stocks today

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

Zacks

5 months ago

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

BioMarin agrees to acquire Inozyme for $270m

Pharmaceutical Technology

5 months ago

BioMarin agrees to acquire Inozyme for $270m

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition

Insider Monkey

5 months ago

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

TipRanks

5 months ago

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

MT Newswires

5 months ago

Top Midday Gainers

BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover

Investor's Business Daily

5 months ago

BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover

MT Newswires

5 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

MT Newswires

5 months ago

Sector Update: Health Care

MT Newswires

5 months ago

BioMarin Pharmaceutical to Acquire Inozyme Pharma for $270 Million

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

PR Newswire

5 months ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress

StockStory

5 months ago

BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress

BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Insider Monkey

5 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Argus Research

5 months ago

BMRN: Rating increased to a BUY

MT Newswires

5 months ago

BioMarin's Voxzogo Reduces Tibial Bowing in Young Children With Achondroplasia

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

PR Newswire

5 months ago

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

Shareholders Will Be Pleased With The Quality of BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings

Simply Wall St.

5 months ago

Shareholders Will Be Pleased With The Quality of BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Zacks

5 months ago

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential

Insider Monkey

5 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential

1 Healthcare Stock with Competitive Advantages and 2 to Brush Off

StockStory

5 months ago

1 Healthcare Stock with Competitive Advantages and 2 to Brush Off

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

StockStory

5 months ago

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

StockStory

5 months ago

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years

Insider Monkey

5 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years

Argus Research

6 months ago

BMRN: Lowering target price to $63.00

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Zacks

6 months ago

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

Zacks

6 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

StockStory

6 months ago

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow

StockStory

6 months ago

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow

Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow

StockStory

6 months ago

Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow

BioMarin Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations

Simply Wall St.

6 months ago

BioMarin Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations

Morningstar Research

6 months ago

Analyst Report: BioMarin Pharmaceutical Inc.

BioMarin's First-Quarter Earnings & Sales Beat Estimates

Zacks

6 months ago

BioMarin's First-Quarter Earnings & Sales Beat Estimates

Thomson Reuters StreetEvents

6 months ago

Q1 2025 BioMarin Pharmaceutical Inc Earnings Call

Biomarin Pharmaceutical Inc (BMRN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

6 months ago

Biomarin Pharmaceutical Inc (BMRN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

6 months ago

BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates

Zacks

6 months ago

BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates

BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets

StockStory

6 months ago

BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets

MT Newswires

6 months ago

BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Rise

Associated Press Finance

6 months ago

BioMarin: Q1 Earnings Snapshot

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

PR Newswire

6 months ago

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

StockStory

6 months ago

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

Insider Monkey

6 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

2 Cash-Producing Stocks with Exciting Potential and 1 to Question

StockStory

6 months ago

2 Cash-Producing Stocks with Exciting Potential and 1 to Question

BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying

Insider Monkey

6 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Zacks

6 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Implied Volatility Surging for BioMarin Stock Options

Zacks

6 months ago

Implied Volatility Surging for BioMarin Stock Options

Argus Research

6 months ago

BMRN: Raising target price to $65.00

1 of Wall Street’s Favorite Stock Worth Your Attention and 2 to Question

StockStory

6 months ago

1 of Wall Street’s Favorite Stock Worth Your Attention and 2 to Question

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Zacks

6 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

6 months ago

Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

PR Newswire

6 months ago

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Zacks

6 months ago

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Zacks

6 months ago

Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

StockStory

6 months ago

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

Argus Research

6 months ago

BMRN: Raising target price to $63.00

MT Newswires

6 months ago

Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin

6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility

Motley Fool

6 months ago

6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?

Zacks

6 months ago

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Zacks

6 months ago

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day

Zacks

6 months ago

Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day

Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On

Zacks

6 months ago

Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On

Argus Research

6 months ago

BMRN: Lowering target price to $59.00

Share on Social Networks: